Lupin has announced acquiring rights to manufacture tuberculosis drug pretomanid from the non-profit drug developer TB Alliance. The deal gives Lupin “a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug ‘BPaL’ regimen,” the partners stated.
The BPaL regimen also includes Johnson & Johnson’s Sirturo (bedaquiline) and Pfizer’s Zyvox (linezolid).






